Study of IgG and IgM antibody response afterPfizer mRNA Vaccine first dose in Previously infected with COVID-19and uninfected individuals

Volume 20 No 8 (2022)

Fadhil Kahdim Jassim ,Aseel kasim kareem , Maher Mohammed Khadairi2 ,Nassar Abdalaema Mera1 , MahirAbdulkadhum Alzughaibi1 , Mohammed Zuhair Naji , Saif Sahib Radhi , Ali Fahim Mohammed , Marowa H Abbas

DOI: 10.14704/nq.2022.20.8.NQ44783

Abstract

The current research aimedto demonstrate the extent such as increase in the rate of immune response to antibodies (IgG, IgM) for people who received the first dose of the Pfizer mRNA vaccine at (1-3) weeks times period and to compare them with people who were not taken for the first dose of the same vaccine and none infected with COVID -19.Also the results appearedsignificant variations in immunoglobulin (IgG) levels (P≤ 0.05) between case (Recipients mRNA vaccination) and control patients, there were. In terms of age and gender, however, there were no significant changes (P≥ 0.05) in immunoglobulin (IgM) levels between case (Recipients mRNA vaccination) and control patients. .

Keywords

COVID-19, Pfizer mRNA Vaccine ,IgG,IgM.

Copyright © Neuroquantology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the Neuroquantology are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJECSE right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.